IndraLab

Statements

reach
"Since these pathways all converge in the same target gene, USP22 can be used as a new target in cancer treatment.USP22 may be a particularly attractive target for cancer immunotherapy, because USP22 c[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"
37769523
reach
"Usp22 and Usp21 deletion in T reg cells synergizes to enhance antitumor immunity."
36427305
reach
"USP22 also restricts antitumor immunity through potentiating regulatory T cell (T ) immune suppressive activity (16) and T adaptation in the tumor microenvironment (17)."
39151008
reach
"What more excited is that USP22 can inhibit the antitumor immunity, efficacy of PDL1 targeted immunotherapy by inhibiting the deubiquitinase of PDL1 (CD274) [XREF_BIBR], which is consistent with our results."
32294625
reach
"In addition, USP22 deubiquitinated CD274 leading to the stabilization of its expression, knockdown of USP22 enhanced the anticancer immunity of CD274 in liver cancer [ 31 ]."
38176298
reach
"The expression of USP22 in tumor cells suppresses anti-tumor immunity and confers resistance to immunotherapy (18)."
35935969
reach
"Based on these observations, the authors hypothesized that USP22 inhibition could simultaneously promote anti-tumor immunity and target tumors driven by USP22 upregulation and pathogenic H2Bub1 deplet[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"
34953650
reach
"Tumor cell-intrinsic USP22 suppresses antitumor immunity in pancreatic cancer."
31871120
reach
"Also, Gregory et al. confirmed an important role for USP22 in suppressing the neoantigen-specific immune response via stabilizing the ecto-5’-nucleotidase (NT5E) in BC [39]."
38347585
reach
"These findings are consistent with the idea that USP22 promotes the non T cell inflamed TME and suppresses antitumor immunity in PDA."
31871120
reach
"Collectively, these experiments suggest that USP22 expression in PDA tumors cells suppresses antitumor immunity and confers resistance to immunotherapy."
31871120
reach
"In mouse models of hepatocellular carcinoma, knockout of Usp22 increases the infiltration of tumor-infiltrating lymphocytes, augments anti-tumor immunity, and synergizes with anti-PD-L1 treatments and chemotherapy (29)."
37415977
reach
"100 Another DUB, USP22, also stabilizes PD-L1 in tumor cells via deubiquitination and suppresses antitumor immunity in mouse tumor models."
33436547